30.76
+0.05
+(0.16%)
At close: April 17 at 4:00:01 PM EDT
30.76
0.00
(0.00%)
After hours: April 17 at 4:36:22 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
661,817
661,817
607,521
667,238
579,775
Cost of Revenue
77,906
77,906
83,779
87,221
75,061
Gross Profit
583,911
583,911
523,742
580,017
504,714
Operating Expense
508,355
508,355
510,339
534,403
425,215
Operating Income
75,556
75,556
13,403
45,614
79,499
Net Non Operating Interest Income Expense
16,204
16,204
8,038
14,619
-12,854
Other Income Expense
6,110
6,110
-18,672
510
6,530
Pretax Income
97,870
97,870
2,769
60,743
73,175
Tax Provision
24,005
24,005
1,453
32
19,751
Net Income Common Stockholders
73,865
73,865
1,316
60,711
53,424
Average Dilution Earnings
--
--
--
3,556
--
Diluted NI Available to Com Stockholders
73,865
73,865
1,316
64,267
53,424
Basic EPS
1.08
1.34
0.02
1.13
1.01
Diluted EPS
1.07
1.32
0.02
1.04
0.98
Basic Average Shares
54,895.17
55,100.06
54,536.28
53,665.14
53,099.33
Diluted Average Shares
55,669.03
55,958.54
55,506.83
61,679.80
54,356.74
Total Operating Income as Reported
81,666
81,666
-5,269
46,124
86,029
Total Expenses
586,261
586,261
594,118
621,624
500,276
Net Income from Continuing & Discontinued Operation
73,865
73,865
1,316
60,711
53,424
Normalized Income
69,282.50
69,282.50
16,066.88
60,201.27
48,656.54
Interest Income
16,204
16,204
10,453
21,689
10,569
Interest Expense
--
--
2,415
7,070
23,423
Net Interest Income
16,204
16,204
8,038
14,619
-12,854
EBIT
97,870
97,870
5,184
67,813
96,598
EBITDA
178,284
178,284
90,043
153,356
129,193
Reconciled Cost of Revenue
75,469
75,469
81,305
84,308
72,455
Reconciled Depreciation
80,414
80,414
84,859
85,543
32,595
Net Income from Continuing Operation Net Minority Interest
73,865
73,865
1,316
60,711
53,424
Total Unusual Items Excluding Goodwill
6,110
6,110
-18,672
510
6,530
Total Unusual Items
6,110
6,110
-18,672
510
6,530
Normalized EBITDA
172,174
172,174
108,715
152,846
122,663
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
1,527.50
1,527.50
-3,921.12
0.27
1,762.54
12/31/2021 - 5/1/2012
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
COLL Collegium Pharmaceutical, Inc.
27.01
-0.04%
PCRX Pacira BioSciences, Inc.
24.65
+0.74%
ETON Eton Pharmaceuticals, Inc.
14.34
+1.85%
PBV.F Prestige Consumer Healthcare Inc.
69.50
0.00%
2DT.F Amneal Pharmaceuticals, Inc.
5.90
-0.84%
29A.SG Amphastar Pharmaceuticals Inc
20.47
+3.36%
29A.MU Amphastar Pharmaceuticals Inc
20.49
-1.87%
PIG.MU Perrigo Co PLC
22.23
+1.46%
PB8.BE Phibro Animal Health Corp
14.70
+2.08%
2DT.SG Amneal Pharmaceuticals Inc
6.40
+4.07%